Welcome to our dedicated page for Bluejay Diagnostics SEC filings (Ticker: BJDX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Bluejay Diagnostics filings document the company’s medical diagnostics business, Nasdaq-listed common stock, and disclosures tied to development of the Symphony™ near-patient testing platform. Form 8-K reports cover corporate updates, financial condition items, Regulation FD disclosures, SYMON clinical-study updates, conference-related product disclosures, manufacturing readiness, and capitalization matters involving warrants and private placements.
The company’s proxy materials describe annual meeting proposals, voting procedures, board and governance matters, and stockholder approval topics. Bluejay’s filings also identify it as an emerging growth company and include formal disclosures on material agreements, registered securities, risk-relevant development activities, and capital-structure changes such as reverse stock splits and warrant exercises.
Bluejay Diagnostics, Inc. filed a current report describing new clinical visibility for its Symphony IL-6 Test. An abstract based on the multicenter SYMON-I pilot study was accepted for presentation at the 2026 Society of Academic Emergency Medicine Annual Meeting in Atlanta.
The presentation will cover how interleukin-6 levels measured in the emergency department relate to organ dysfunction, assessed by Sequential Organ Failure Assessment scores over the first three days of hospitalization in sepsis patients. Bluejay also highlights its ongoing SYMON-II validation study, intended to further evaluate IL-6 as a prognostic biomarker linked to mortality and other clinically meaningful outcomes in critically ill patients.
Bluejay Diagnostics, Inc. faces new shareholder pressure as Northstrive Fund II LP and Braeden Lichti file a Schedule 13D on the company’s common stock. As of March 10, 2026, Lichti beneficially owns 35,500 shares, or 3.65% of the 972,000 shares outstanding, while Northstrive Fund II LP owns 11,000 shares, or 1.13%.
The investors sent a March 11, 2026 letter to Bluejay’s board recommending review of a potential biotechnology acquisition they identified to strengthen the clinical pipeline and, in their view, accelerate shareholder value creation. They signal possible future changes in their position, including buying more or selling shares, and may consider actions that could influence control of the company.
Bluejay Diagnostics, Inc. received an updated ownership filing from investor Braeden Lichti and Northstrive Fund II LP, who are now reporting as active investors. As of March 10, 2026, Lichti beneficially owned 35,500 shares of common stock, or 3.65% of the company, while Northstrive Fund II LP owned 11,000 shares, or 1.13%. Both stakes are calculated against 972,000 shares outstanding, as reported in a recent company press release. The investors sent a letter to Bluejay’s board on March 11, 2026, recommending that the board review a potential biotechnology acquisition opportunity that they believe could strengthen the clinical pipeline and accelerate shareholder value. Because this communication may be intended to influence control or strategy, they switched from a passive Schedule 13G to this Schedule 13D and state they may buy more, sell, or pursue other strategic actions over time.
Northstrive Fund II LP and Braeden Lichti have filed a Schedule 13D on Bluejay Diagnostics, Inc. They report beneficial ownership of 11,000 and 35,500 shares of common stock, respectively, representing 1.13% and 3.65% of the 972,000 shares outstanding as referenced in a recent company press release.
The filing discloses a letter sent on March 11, 2026 to Bluejay’s board recommending that it review a potential biotechnology acquisition opportunity identified by Northstrive to strengthen the clinical pipeline. The investors indicate they may increase or reduce their stake over time and may consider actions that could influence control of the company.
Bluejay Diagnostics, Inc. is a development‑stage medical diagnostics company focused on its Symphony platform and an IL‑6 test for assessing 28‑day mortality risk in sepsis and septic shock patients in ICUs. Symphony is not yet FDA cleared, and the company has no revenue‑generating operations.
Bluejay has completed pre‑clinical development of the Symphony analyzer and is working with contract manufacturer Sanyoseiko in Japan to redevelop and validate disposable cartridges for FDA submission and future commercialization. A pivotal SYMON‑II clinical trial is underway, with about 583 of a targeted 750 patients enrolled and samples biobanked for later testing.
As of December 31, 2025, the company reported an accumulated deficit of about $41.5 million and an operating loss of roughly $6.8 million for 2025. Management expects to raise at least $20 million by the end of fiscal 2027 to execute its plan to analyze SYMON‑II samples in 2026, submit a 510(k) application in 2027 and pursue FDA clearance, and warns it may run out of cash in the third quarter of 2026 without new capital.
The filing highlights substantial risks, including going‑concern uncertainty, dependence on Toray’s cartridge IP and Sanyoseiko’s manufacturing, multiple highly dilutive financings and reverse stock splits aggregating 1‑for‑32,000 since July 2023, extensive outstanding warrants, and the possibility of Nasdaq delisting based on minimum bid price, market value and a proposed $5 million market value of listed securities standard.
Bluejay Diagnostics, Inc. filed a current report after issuing a press release that outlines its 2026 strategic outlook and recent progress. The company continues advancing its Symphony platform and SYMON II clinical study for an Interleukin-6 test to support sepsis risk assessment, with enrollment and site activity proceeding as planned for regulatory purposes.
Bluejay reports ongoing manufacturing scale-up, supply-chain work, and process validation to prepare for potential commercialization. During February 2026, previously issued prefunded warrants were fully exercised and converted into common shares, leaving approximately 972,000 common shares outstanding plus cash-exercisable warrants with strike prices above current trading levels.
The company expects to report $5.2 million in cash and cash equivalents and $6.0 million in stockholders’ equity as of December 31, 2025, after a $3.8 million warrant-inducement financing in April 2025 and a $4.5 million PIPE in October 2025. Net loss for 2025 was about $6.8 million. Management states that 2026 priorities center on clinical validation, manufacturing readiness, and positioning the Symphony platform for future regulatory submission and commercialization.
Bluejay Diagnostics, Inc. reported that all prefunded warrants issued in its October 2025 private placement were fully exercised as of February 19, 2026, leaving no prefunded warrants outstanding. After these exercises, the company has approximately 972,000 shares of common stock outstanding.
The company also has cash exercisable warrants outstanding for approximately 1.5 million shares, all with a cash exercise price of $7.00 or higher per share. Bluejay highlighted that several recent Schedule 13G filings do not reflect its 1-for-4 reverse stock split completed on January 29, 2026, so share amounts in those reports may appear higher than current post-split ownership.
Bluejay Diagnostics, Inc. ownership disclosure: Armistice Capital, LLC and Steven Boyd report beneficial ownership of 194,132 shares of common stock, representing 9.99% of the class as of 12/31/2025. The filing states Armistice Capital is investment manager of the direct holder, Armistice Capital Master Fund Ltd.
The report attributes shared voting and dispositive power of 194,132 shares to the Reporting Persons and notes the Master Fund retains economic rights; signatures dated 02/18/2026.
Bluejay Diagnostics ownership disclosure: Armistice Capital, LLC and Steven Boyd report beneficial ownership of 194,132 shares, representing 9.99% of common stock as of 12/31/2025.
The filing states the shares are held directly by Armistice Capital Master Fund Ltd., for which Armistice Capital is investment manager and Steven Boyd is managing member; the Master Fund disclaims direct voting or dispositive power under its Investment Management Agreement.
Bluejay Diagnostics filed a current report describing clinical and operational progress for its Symphony System and IL-6 sepsis test. The company has enrolled 545 patients in its multicenter SYMON™ II IL-6 monitoring study, toward a stated target of 750 patients, which management says exceeds initial expectations and reduces enrollment execution risk. All patients have been enrolled under approved IRB protocols, and management believes the growing, diverse dataset will support future regulatory and partner discussions.
Bluejay also highlights continued advancement of manufacturing readiness across antibodies, tooling, analytical validation, and commercial manufacturing infrastructure, with technology transfer designed to avoid single points of failure. The company reiterates that its Symphony System does not yet have FDA regulatory clearance and cannot be marketed as a diagnostic product in the United States until authorization is obtained.